Long‐term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real‐world retrospective study
- 27 March 2024
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (10) , e892-e895
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trialsNature Medicine, 2023
- Investigator’s Global Assessment of Chronic Prurigo: A New Instrument for Use in Clinical TrialsActa Dermato-Venereologica, 2021
- Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to responseJournal of Dermatological Treatment, 2020
- Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigoJournal of the American Academy of Dermatology, 2020
- Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularisBritish Journal of Dermatology, 2011
- Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigoEuropean Journal Of Dermatology, 2011